Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.

@article{Chen2013SerumMP,
  title={Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.},
  author={Qi Chen and Hong-Wei Xia and Xiao-Jun Ge and Yu-Chen Zhang and Qiu-lin Tang and Feng Bi},
  journal={Asian Pacific journal of cancer prevention : APJCP},
  year={2013},
  volume={14 12},
  pages={7421-6}
}
  • Qi Chen, Hong-Wei Xia, +3 authors Feng Bi
  • Published 2013 in
    Asian Pacific journal of cancer prevention…
BACKGROUND Colorectal cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death. FOLFOX is the most common regimen used in the first-line chemotherapy in advanced colorectal cancer, but only half of the patients respond to this regimen and we have almost no clue in predicting resistance in such first-line application. METHODS To explore the potential molecular biomarkers predicting the resistance of FOLFOX regimen as the first-line treatment in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Phase III trial

  • A Falcone, S Ricci, I Brunetti
  • Nat Genet,
  • 2007
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…